Sign Up to like & get
recommendations!
0
Published in 2019 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2019.37.4_suppl.95
Abstract: 95 Background: The treatment option for ESCC patients (pts) progressing after chemotherapy is still uncertain. Anlotinib is a multi-target tyrosine kinase inhibitor involved in tumor angiogenesis and growth, such as vascular endothelia growth factor receptor…
read more here.
Keywords:
chemotherapy;
anlotinib;
placebo;
day ... See more keywords